Financial Results Presentation for the Second Quarter of the Fiscal Year Ending March 2027 | JMDC Inc. (4483) timely disclosure

Worth reading

54Recurring

0–100. This measures how worthwhile something is to read, not how good or bad the company is.

Direction

Improvement

Direction inferred from the company’s description.

Scale

Year-on-year change in consolidated revenue (%)

Wording

Conditional

How definitive the wording is.

Contents of this document

Earnings presentation materialsSecond quarter of the fiscal year ending March 20277 items taken from the company’s own explanation

Financial Results Figures (The key points of this material are explained below)

Net Sales¥27,571 million+19.0%

Operating profit¥4,604 million+14.0%

Ordinary income¥4,340 million +19.0%profit before tax, IFRS

Net income¥2,951 millions +24.0%profit attributable to owners of the parent

Operating profit margin17 %

Results for the three months of the current quarterRevenue growth for Q2 alone was +21% year on year, while EBITDA growth was +13% year on year. Standalone quarterly revenue and EBITDA figures are also included in the quarterly trend chart.

Full-year earnings forecast

Revenue

¥60,500 million

Operating profit

¥11,500 million

Pretax profit

¥11,000 million

Profit attributable to owners of the parent

¥7,100 million

EBITDA

¥15,000 million

Progress against full-year forecast　通期の予想に対して、いまどこまで進んだかの割合です。

Revenue46%

Operating profit40%

Pretax profit39%

Profit attributable to owners of the parent42%

EBITDA42%

What the company explained in this material

Self-assessment against the planThe company's self-assessment against its own plan.

First-half revenue, operating profit and EBITDA all exceeded the first-half forecast. Full-year guidance was unchanged.

Key points of the Q&AKey questions raised by investors at the briefing and the company's answers

First-half revenue, operating profit and EBITDA all exceeded the first-half forecast.
Growth for industry customers was driven by expansion among pharmaceutical companies' sales and marketing and medical departments, as well as insurance and other companies.
No major security incidents have occurred, and the company responds through NIST CSF, EDR, SASE and a 24/7 SOC, among other measures.
The EBITDA growth rate required in the second half is approximately +13%, and full-year guidance was unchanged.

Assumptions Underlying the Business OutlookThe assumptions used by the company in preparing its forecast.

The EBITDA growth rate required to achieve the full-year plan in the second half is approximately +13%.

New initiatives

Investment in AI-related personnel and data infrastructure
Strengthening the Sales Organization
Building real-time predictive models using local government and medical institution data
Developing a real-time predictive model for SAS (sleep apnea syndrome)

Key KPIsA metric the company considers important as a management benchmark.

Industry transaction value36 % year on year
Transaction value with pharmaceutical companies28 % year on year
For sales and marketing departments57 % year on year
For medical departments29 % year on year
For life and non-life insurance companies79 % year on year
For other enterprise customers67 % year on year
Business revenue from insurers and consumers6 % year on year
Business revenue from healthcare providers21 % year on year
Revenue from local government data85 % year on year
Revenue from medical institution data106 % year on year

Segment results

Health Big Data

Sales

¥24,152 million+21.0%

EBITDA

¥5,511 million+15.0%

EBITDA margin23%

Telemedicine

Sales

¥3,419 million+7.0%

EBITDA

¥1,370 million+19.0%

EBITDA margin40%

Adjustments

Sales

¥0 million

EBITDA

¥-548 million

Market Size / Share

Market share among local governmentsApproximately 50%
Number of local governments1,716 Local governments
Industry share in telemedicine30 %
Coverage rate among health insurance societies and mutual aid associations56 %
Coverage rate among local governments52 %
Coverage rate among medical institutions51 %

Contents of this document
Item	Details
Document type	Earnings presentation materials
Fiscal Period Covered	Second quarter of the fiscal year ending March 2027
Net Sales	¥27,571 million (YoY +19.0%)
Operating profit	¥4,604 million (YoY +14.0%)
Ordinary income	¥4,340 million (profit before tax, IFRS) (YoY +19.0%)
Net income	¥2,951 millions (profit attributable to owners of the parent) (YoY +24.0%)
Operating profit margin	17 %
Results for the three months of the current quarter	Revenue growth for Q2 alone was +21% year on year, while EBITDA growth was +13% year on year. Standalone quarterly revenue and EBITDA figures are also included in the quarterly trend chart.
Full-year earnings forecast	Revenue ¥60,500 million / Operating profit ¥11,500 million / Pretax profit ¥11,000 million / Profit attributable to owners of the parent ¥7,100 million / EBITDA ¥15,000 million
Progress against full-year forecast	Revenue 46% / Operating profit 40% / Pretax profit 39% / Profit attributable to owners of the parent 42% / EBITDA 42%
Self-assessment against the plan	First-half revenue, operating profit and EBITDA all exceeded the first-half forecast. Full-year guidance was unchanged.
Segment results	Health Big Data Sales ¥24,152 million (YoY +21.0%) / EBITDA ¥5,511 million (YoY +15.0%) / EBITDA margin 23% / Telemedicine Sales ¥3,419 million (YoY +7.0%) / EBITDA ¥1,370 million (YoY +19.0%) / EBITDA margin 40% / Adjustments Sales ¥0 million / EBITDA ¥-548 million
Key KPIs	Indicator name Industry transaction value / Value 36 % year on year, Indicator name Transaction value with pharmaceutical companies / Value 28 % year on year, Indicator name For sales and marketing departments / Value 57 % year on year, Indicator name For medical departments / Value 29 % year on year, Indicator name For life and non-life insurance companies / Value 79 % year on year, Indicator name For other enterprise customers / Value 67 % year on year, Indicator name Business revenue from insurers and consumers / Value 6 % year on year, Indicator name Business revenue from healthcare providers / Value 21 % year on year, Indicator name Revenue from local government data / Value 85 % year on year, Indicator name Revenue from medical institution data / Value 106 % year on year
Assumptions Underlying the Business Outlook	The EBITDA growth rate required to achieve the full-year plan in the second half is approximately +13%.
Market Size / Share	Subject Market share among local governments / Value Approximately 50%, Subject Number of local governments / Value 1,716 Local governments, Subject Industry share in telemedicine / Value 30 %, Subject Coverage rate among health insurance societies and mutual aid associations / Value 56 %, Subject Coverage rate among local governments / Value 52 %, Subject Coverage rate among medical institutions / Value 51 %
Key points of the Q&A	First-half revenue, operating profit and EBITDA all exceeded the first-half forecast., Growth for industry customers was driven by expansion among pharmaceutical companies' sales and marketing and medical departments, as well as insurance and other companies., No major security incidents have occurred, and the company responds through NIST CSF, EDR, SASE and a 24/7 SOC, among other measures., The EBITDA growth rate required in the second half is approximately +13%, and full-year guidance was unchanged.
New initiatives	Investment in AI-related personnel and data infrastructure, Strengthening the Sales Organization, Building real-time predictive models using local government and medical institution data, Developing a real-time predictive model for SAS (sleep apnea syndrome)

Items this document does not state (14)

Gross Profit MarginSelling, general and administrative expensesBreakdown of Factors Affecting the ChangeUnit price and quantity metricsNumber of stores and locationsNumber of employeesRisk amount incorporated into the outlookMedium-term management plan targetsFinancial targetsAnnual DividendPayout ratioAcquisition of treasury sharesCapital expendituresOrders received and order backlog

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

Growth in health big data, primarily for industry customers, deeper penetration into the sales and marketing and medical departments of pharmaceutical companies, expansion of high-value-added services, and broader use of data from local governments and medical institutions contributed. Telemedicine also grew on steady demand and strengthened operations.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.

Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.

Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.